STOCK TITAN

Revance to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will be participating in two investor conferences: Stifel 2023 Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. The Chief Financial Officer, Tobin Schilke, will participate in a fireside chat on November 14, 2023, at 11:30 A.M. EST, while the Chief Executive Officer, Mark Foley, will participate in a fireside chat on November 28, 2023, at 3:00 P.M. EST. Interested parties can access the live audio webcasts from the company's website. Webcast replays will be available for approximately 90 days.
Positive
  • None.
Negative
  • None.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.

Stifel 2023 Healthcare Conference
Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, November 14, 2023, at 11:30 A.M. EST, in New York City, New York.

Piper Sandler 35th Annual Healthcare Conference
Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, November 28, 2023, at 3:00 P.M. EST, in New York City, New York.

Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.

Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif.

Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.

Investors

Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886

jessica.serra@revance.com

or

Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620

laurence@gilmartinir.com

Media

Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

sfahy@revance.com

Source: Revance Therapeutics, Inc.

Revance Therapeutics will be participating in the Stifel 2023 Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference.

The Chief Financial Officer, Tobin Schilke, will participate in a fireside chat on November 14, 2023, and the Chief Executive Officer, Mark Foley, will participate in a fireside chat on November 28, 2023.

The investor conferences will take place in New York City, New York.

Interested parties can access the live audio webcasts from the Investor Relations section of Revance Therapeutics' website at www.revance.com.

The webcast replays will be available for approximately 90 days.
Revance Therapeutics Inc

NASDAQ:RVNC

RVNC Rankings

RVNC Latest News

RVNC Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Newark

About RVNC

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form